National Institute for Health and Clinical Excellence (NICE)
Innovative technology to detect abnormal heart rhythms recommended by NICE for NHS use while further data is collected
Zio ZT is the first assessment, via the NICE digital health technologies guidance development pilot project, to be recommended for NHS use with the caveat that further data must be collected.
NICE yesterday published medical technology guidance which recommends the Zio XT service for detecting abnormal heart rhythms, only if NHS organisations collect further evidence of its benefits.
Patients will have access to this promising new technology for three years while more data is collected to address evidence gaps about its benefit. After this time, NICE’s committee will review the technology with the new evidence and make a final recommendation on whether to recommend Zio XT for routine use on the NHS.
More than 1.2 million people in the UK are diagnosed with having atrial fibrillation (AF), one of the most common cardiac arrhythmias, an abnormality of the heart's rhythm. Another 500,000 people are believed to be living with undiagnosed AF. Zio XT service could – if commissioned by the NHS – be used by more than 150,000 people.
The Zio XT service comprises a waterproof biosensor patch and a report with a summary of data that has been analysed using an artificial intelligence (AI) led algorithm. The biosensor patch is a small, lightweight, easy to wear electrocardiogram (ECG), that records and measures the heart's electrical activity. It is worn constantly for up to 14 days and can be fitted by a patient at home, discreetly underneath their clothes.
As the patch can be worn for up to two weeks, the amount of analysable data is larger than the 24-hour Holter monitor which is current NHS standard practice and therefore Zio XT is more likely to pick up arrhythmia. After use the patient removes the patch and sends it via freepost for analysis.
The ECG recordings are analysed using an artificial intelligence developed algorithm, overseen by the company’s cardiographic technicians. A full report is then supplied to the NHS clinician for final analysis and interpretation.
The process can be contact free, especially useful during the COVID-19 pandemic, allowing the patient to first have a telephone/video consultation before the Zio XT biosensor is dispatched direct to their home.
Currently 12 hospital trusts across England are evaluating the Zio XT service, which costs £265 per patient.
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, yesterday said:
“This easy to use and innovative technology can aid the detection of cardiac arrhythmias with continuous monitoring for up to 14 days while allowing the patient to get on with their everyday life.
“The evidence shows that Zio XT increases how many people are diagnosed with cardiac arrhythmias. The diagnostic accuracy of the artificial intelligence led algorithm looked to perform well in recognising arrhythmias.
“While we are pleased to recommend the use of Zio XT service, our committee has requested further data must be collected to allow us to fully understand its impact on NHS resources and the long-term consequences of its use.”
Earlier this year Zio XT's developer, iRhythm technologies, were winners of the Artificial Intelligence in Health and Care Award run by the Accelerated Access Collaborative with NHSX and NIHR.
Indra Joshi, director of AI at NHSX, yesterday said:
“We will be testing ZIO XT and a number of other cutting edge technologies through our AI Lab in NHS services up and down the country to see how they could safely help patients and save resources.
"If the tests work well, it could generate the evidence for wider adoption across the NHS of an important potential heart disease detection tool."
Zio XT is likely to be cost saving or similar in cost as using 24-hour Holter monitoring – a portable heart recording device fitted by a technician in a healthcare setting, who places electrodes on the patient’s chest to record their heartbeat for up to seven days.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Children and young people need accurate, accessible information about their healthcare05/03/2021 11:25:00
New draft guidance from NICE published today recommends ensuring children and young people are fully informed about their health so that they are empowered to take an active role in their healthcare
Register now for the HTAi 2021 Virtual Annual Meeting05/03/2021 11:15:00
The Health Technology Assessment International (HTAi) 2021 Annual Meeting will be held virtually from 19-23 June 2021, and registration is now open.
Thousands of breast cancer patients to have routine access to NICE-approved drug combination01/03/2021 15:28:15
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer26/02/2021 16:15:00
Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition.
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE25/02/2021 15:20:00
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria25/02/2021 14:15:00
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
A new instrument for consideration of a broader range of benefits for people, their families and carers18/02/2021 14:15:00
Blog posted by: Bhash Naidoo Senior Technical Adviser – Health Economics at NICE, 17 February 2021.
Skin cancer drug recommended for routine NHS use15/02/2021 09:15:00
An appeal period has now opened until 26 February 2021.
NICE recommends treatment options for severe pregnancy sickness in new draft guidance11/02/2021 15:15:00
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptoms, with most conditions improving or stopping completely by around 16 to 20 weeks